![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NEUROPTIX ANNOUNCES BREAKTHROUGH PRECLINICAL TESTS OF OPTISCAN PLATFORM FOR NON-INVASIVE EARLY DETECTION OF ALZHEIMER'S
NEUROPTIX ANNOUNCES BREAKTHROUGH PRECLINICAL TESTS OF OPTISCAN PLATFORM FOR NON-INVASIVE EARLY DETECTION OF ALZHEIMER'S
September 13, 2006
Neuroptix Corporation, a Massachusetts-based Alzheimer's diagnostics company, announced that recent tests of its Optiscan diagnostic platform on mice demonstrated that the optical scanning system was able to detect amyloid protein aggregates in the lens of the eye prior to toxic plaque build-up in the brain.
Genetic
Engineering News
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct